Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Trial Profile

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jul 2016

At a glance

  • Drugs E 7016 (Primary) ; Temozolomide
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 18 Apr 2014 Planned End Date changed from 1 Mar 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
    • 28 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 29 May 2012 Status changed from planning to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top